Judd Cahoon
Ophthalmology · Salt Lake City, UTNPI 1699126680
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 183 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Alcon at 27.2% of the total. 2025 is the largest year on record at $1,586, 2.3 times the $679 reported in 2019.
Across 183 payments — averaging $29.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$573
- Amgen$557
- Bausch & Lomb Americas Inc.$485
- Aerie Pharmaceuticals, Inc.$308
- Harrow Eye, LLC$288
- plus $2K from 16 others
What the payments were for
- Speaking & faculty fees$391%
- Food & beverage$5,33598%
- Entertainment$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 39 | $1,476 |
| AbbVie(2 entities) | 22 | $573 |
| Amgen(2 entities) | 21 | $557 |
| Bausch & Lomb Americas Inc. | 19 | $485 |
| Aerie Pharmaceuticals, Inc. | 13 | $308 |
| Harrow Eye, LLC | 7 | $288 |
| Rxsight Inc | 7 | $260 |
| Sight Sciences, Inc. | 5 | $208 |
| Oyster Point Pharma, Inc. | 6 | $173 |
| Tarsus Pharmaceuticals, Inc. | 6 | $162 |
| Sun Pharmaceutical Industries Inc. | 6 | $155 |
| Thea Pharma Inc. | 7 | $143 |
| Biotissue Holdings Inc. | 6 | $141 |
| Nova Eye, Inc. | 1 | $128 |
| ANI Pharmaceuticals, Inc. | 4 | $82 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $68 |
| Optos, Inc. | 2 | $50 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $49 |
| Eyevance Pharmaceuticals LLC | 3 | $42 |
| Glaukos Corporation | 2 | $37 |
| Kala Pharmaceuticals, Inc. | 1 | $22 |
| Akorn, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,423 in reported general payments places this provider in the 85th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 27 | $35,045 |
| XiidraLifitegrast | 26 | $32,582 |
| RhopressaNetarsudil Mesylate | 37 | $18,057 |
| LumiganBimatoprost | 31 | $17,570 |
| VyzultaLatanoprostene Bunod | 38 | $15,807 |
| Cyclosporine | 15 | $7,921 |
| Cosopt PfDorzolamide/Timolol/Pf | 13 | $7,078 |
| ZyletTobramycin/Lotepred Etab | 13 | $5,074 |
| Alphagan PBrimonidine Tartrate | 18 | $4,689 |
| CombiganBrimonidine Tartrate/Timolol | 12 | $4,411 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,380 |
| TafluprostTafluprost/Pf | 14 | $3,200 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 13 | $2,191 |
| Bromfenac Sodium | 13 | $2,035 |
| Timolol Maleate | 140 | $1,412 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $573 | $61,71588 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $485 | $48,38964 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $308 | $18,05737 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCZylet | $68 | $5,07413 claims |
| AlconSimbrinza | $1,476 | $3,38017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in Salt Lake City
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
- Rachel SimpsonSalt Lake City$39K
- Austin NakatsukaSalt Lake City$27K
- Douglas MarxSalt Lake City$22K
- Akbar ShakoorSalt Lake City$18K
- Craig ChayaSalt Lake City$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.